Regeneron Pharmaceuticals, Inc.
REGNAction· NasdaqGS· USD
L'essentiel à retenir
- • Dernier cours : 734,81 $US (cours différé)
- • Variation sur 1 an : +22,47 %
- • Type d'actif : Action
- • Place de cotation : NasdaqGS
- • Devise de cotation : USD
- • Clôture précédente : 758,27 $US
Informations
- Symbole
- REGN
- Type
- Action
- Place
- NasdaqGS
- Devise
- USD
- Clôture veille
- 758,27 $US
- Variation 1 an
- +22,47 %
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial Regeneron has been enrolling a dedicated LGSOC cohort at this dose and will ad
Yahoo Finance · 01/10/2026 · lire l'article ↗
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharm
Yahoo Finance · 01/10/2026 · lire l'article ↗
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew
Yahoo Finance · 01/10/2026 · lire l'article ↗
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
Yahoo Finance · 01/10/2026 · lire l'article ↗
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu
Yahoo Finance · 01/10/2026 · lire l'article ↗
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.
Yahoo Finance · 01/10/2026 · lire l'article ↗
Titres et résumés fournis par les sources d'origine (flux Yahoo Finance). Cliquez pour lire l'article complet.
Questions fréquentes sur Regeneron Pharmaceuticals, Inc.
- Quel est le cours actuel de Regeneron Pharmaceuticals, Inc. ?
- Le dernier cours connu de Regeneron Pharmaceuticals, Inc. (REGN) est de 734,81 $US (cours différé, fourni à titre informatif). Cette page est mise à jour régulièrement.
- Quelle est la performance de Regeneron Pharmaceuticals, Inc. sur un an ?
- Sur les 12 derniers mois, Regeneron Pharmaceuticals, Inc. (REGN) affiche une variation de +22,47 %. Les performances passées ne préjugent pas des performances futures.
- Comment suivre Regeneron Pharmaceuticals, Inc. dans mon portefeuille ?
- Créez un compte gratuit sur AssetApp, ajoutez REGN à l'un de vos portefeuilles et suivez sa valeur, vos plus-values et son actualité — aux côtés de vos autres actifs.
Actifs similaires
Regeneron Pharmaceuticals, Inc. : suivre cet actif
Regeneron Pharmaceuticals, Inc. (REGN) est une action coté sur NasdaqGS en USD. Avec AssetApp, ajoutez REGN à votre portefeuille pour suivre sa valeur, vos gains latents et réalisés, et l'évolution de votre patrimoine — sans dépendre de votre courtier.
Suivre REGN gratuitement